The Shkreli Pill

• Consider long ASML as the clearest stated semiconductor pick; the speaker preferred it over TSM and LRCX because its chipmaking equipment is difficult to replicate.
• A relative-value trade mentioned was long NVDA / short AMD, reflecting a preference for Nvidia and concern that AMD’s roughly $1 trillion valuation requires exceptionally strong, sustained growth; no target or timeframe was provided.
• Short IONQ was the speaker’s current stance, tied partly to concerns about acquisitions, but the thesis needs further analysis and has no stated price target.
• Treat NVO cautiously after its reported 7–8% decline: the speaker was tempted to buy, but generic Ozempic competition and rival treatments leave the outlook uncertain.

Consider establishing a long position in Ultragenyx Pharmaceutical (RARE) on pullbacks near $13, targeting $30 to $40 over a one-year horizon on drug commercialization and potential acquisition interest from BioMarin (BMRN).

Allocate core tech capital toward liquid large-cap semiconductor leaders like Taiwan Semiconductor (TSM), ASML Holding (ASML), and Lam Research (LRCX) for consistent gains rather than chasing volatile small-cap stocks.

Track international trading data from foreign suppliers like SK Hynix to gain an early directional edge on correlated memory and storage assets.

Look for short-term trading opportunities to fade morning price surges in AI infrastructure and GPU cloud providers like Nebius Group (NBIS) when rallies are driven by already-known industry news.

To protect your capital, limit individual trade sizing to 1% to 2% of your total portfolio so positions can comfortably absorb normal market swings.

Investors should maintain a bullish stance on semiconductor leader Micron Technology (MU), targeting upside price levels between $1,050 and $1,100. Capitalize on the AI infrastructure expansion by purchasing Bloom Energy (BE) to capture data center power demand, while accumulating shares of Meta Platforms (META) on any market pullbacks. Look for short opportunities in IonQ (IONQ) following speculative rallies toward $39 that lack fundamental revenue support. Consider short positions or underweight allocations in Pfizer (PFE) and Nebius Group (NBIS) due to weak pharmaceutical pipelines and uncompetitive cloud pricing moves. Finally, immediately exit or avoid common shares of QCLS (QCLS) to protect capital from severe dilution risks tied to predatory warrants.

Consider establishing a long position in Ultragenyx Pharmaceutical Inc. (RARE), as the stock is deeply undervalued with high expectations for upcoming FDA gene therapy approvals.

Immediately avoid or divest from Quantum Computing Inc. (QCLS) due to toxic financing structures and anti-dilutive warrants that heavily disadvantage common shareholders.

Prepare for a steep decline in Sellas Life Sciences Group (SLS) over the next month ahead of anticipated poor clinical trial outcomes.

Look to trim positions or take profits on Advanced Micro Devices, Inc. (AMD) as it trades near the $150–$155 range, where cost increases from Taiwan Semiconductor Manufacturing Company (TSM) could pressure profit margins.

Treat micro-cap meme coins on platforms like Pump.fun strictly as fast, intraday trading opportunities rather than long-term investments due to extreme liquidity drain risks.